In today’s crowded cannabis landscape, where “premium” is often used as a buzzword, The Medocann Group is setting a higher bar. Founded on nearly a century of family farming heritage and powered by state-of-the-art biotechnology, the Israeli company is redefining what premium truly means: consistency, purity, and precision at every stage of cultivation.
As part of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub we speak with Asaf Sella, Co-Founder and CEO, and Narkis Tessler, Chief of Strategy and Business Development, about Medocann’s philosophy, the technology behind their SMART indoor facility, and how they’re building long-term partnerships to take their craft cannabis to the global stage.
From pesticide-free cultivation and small-batch craftsmanship to patient loyalty and strategic international expansion, the discussion explores how Medocann is combining legacy, science, and vision to shape the future of ultra-premium cannabis.

Farming Meets Precision Engineering
“We approach cultivation not as farming alone, but as precision-driven biotechnology,” explains Asaf Sella, Co-Founder and CEO of Medocann. “Our SMART indoor facility is designed to maintain total environmental control — light, humidity, airflow, nutrients — allowing us to cultivate with zero pesticides and zero compromise.”
Unlike traditional greenhouse or hybrid set-ups, Medocann’s closed-loop indoor system ensures uniformity across every batch, every time. The team leverages data analytics, advanced automation, and real-time plant monitoring to optimize for potency, terpene retention, and cleanliness. The result? Predictable excellence, backed by rigorous quality assurance protocols and built to EU-GMP standards.
Beyond “Premium” — A New Global Standard
Medocann’s products are anything but off-the-shelf. The company cultivates in small batches, hand-trims every flower, and slow-cures each harvest to protect the delicate trichomes holding the cannabinoid and terpene profile of each cultivar. This care is reflected in its two signature lines: SEVEN, a therapeutic-grade collection trusted by Israeli patients and clinicians, and SOLO, an ultra-premium craft collection for cannabis connoisseurs.
“There’s a lot of talk about premium in this space, but for us, it’s a discipline,” says Sella. “Every decision — from phenohunting to post-harvest handling — is made to serve the integrity of the plant and the experience of the consumer.”

Strategic Global Expansion with Select Partners
With a mature domestic footprint in Israel — one of the most regulated and quality-driven cannabis markets globally — Medocann is now actively expanding its international presence.
“Our focus is on long-term partnerships with top-tier distributors who recognise the value of consistency, differentiation, and trust,” says Narkis Tessler, Chief of Strategy and Business Development. “We’re not looking to be just another supplier — we’re seeking partners who are committed to building long-term brand equity in the ultra-premium cannabis space.”
Known for their consistency and efficacy, Medocann’s SEVEN products quickly earn patient loyalty — driving repeat demand and helping partners build a strong, premium presence in their markets.
A Future Built on Integrity, Innovation, and Trust
As regulatory frameworks evolve and consumer expectations sharpen, Medocann believes the cannabis industry is entering its quality-first era.
“We see cannabis moving from commodity to connoisseurship,” says Tessler. “The future belongs to companies that can consistently deliver safety, efficacy, and elevated experiences — not just once, but every single time.”
With its SMART indoor facility, pesticide-free commitment, and a growing international footprint, The Medocann Group is ready to meet that future — and help shape it.
Interested in partnering with Medocann? Visit www.medocann.com or contact us (info@medocann.com) to explore how we can bring ultra-premium craft cannabis to your market — together.
Cultivating Precision: Medocann’s Vision for Ultra-Premium Craft Cannabis on the Global Stage
In today’s crowded cannabis landscape, where “premium” is often used as a buzzword, The Medocann Group is setting a higher bar. Founded on nearly a century of family farming heritage and powered by state-of-the-art biotechnology, the Israeli company is redefining what premium truly means: consistency, purity, and precision at every stage of cultivation.
As part of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub we speak with Asaf Sella, Co-Founder and CEO, and Narkis Tessler, Chief of Strategy and Business Development, about Medocann’s philosophy, the technology behind their SMART indoor facility, and how they’re building long-term partnerships to take their craft cannabis to the global stage.
From pesticide-free cultivation and small-batch craftsmanship to patient loyalty and strategic international expansion, the discussion explores how Medocann is combining legacy, science, and vision to shape the future of ultra-premium cannabis.
Farming Meets Precision Engineering
“We approach cultivation not as farming alone, but as precision-driven biotechnology,” explains Asaf Sella, Co-Founder and CEO of Medocann. “Our SMART indoor facility is designed to maintain total environmental control — light, humidity, airflow, nutrients — allowing us to cultivate with zero pesticides and zero compromise.”
Unlike traditional greenhouse or hybrid set-ups, Medocann’s closed-loop indoor system ensures uniformity across every batch, every time. The team leverages data analytics, advanced automation, and real-time plant monitoring to optimize for potency, terpene retention, and cleanliness. The result? Predictable excellence, backed by rigorous quality assurance protocols and built to EU-GMP standards.
Beyond “Premium” — A New Global Standard
Medocann’s products are anything but off-the-shelf. The company cultivates in small batches, hand-trims every flower, and slow-cures each harvest to protect the delicate trichomes holding the cannabinoid and terpene profile of each cultivar. This care is reflected in its two signature lines: SEVEN, a therapeutic-grade collection trusted by Israeli patients and clinicians, and SOLO, an ultra-premium craft collection for cannabis connoisseurs.
“There’s a lot of talk about premium in this space, but for us, it’s a discipline,” says Sella. “Every decision — from phenohunting to post-harvest handling — is made to serve the integrity of the plant and the experience of the consumer.”
Strategic Global Expansion with Select Partners
With a mature domestic footprint in Israel — one of the most regulated and quality-driven cannabis markets globally — Medocann is now actively expanding its international presence.
“Our focus is on long-term partnerships with top-tier distributors who recognise the value of consistency, differentiation, and trust,” says Narkis Tessler, Chief of Strategy and Business Development. “We’re not looking to be just another supplier — we’re seeking partners who are committed to building long-term brand equity in the ultra-premium cannabis space.”
Known for their consistency and efficacy, Medocann’s SEVEN products quickly earn patient loyalty — driving repeat demand and helping partners build a strong, premium presence in their markets.
A Future Built on Integrity, Innovation, and Trust
As regulatory frameworks evolve and consumer expectations sharpen, Medocann believes the cannabis industry is entering its quality-first era.
“We see cannabis moving from commodity to connoisseurship,” says Tessler. “The future belongs to companies that can consistently deliver safety, efficacy, and elevated experiences — not just once, but every single time.”
With its SMART indoor facility, pesticide-free commitment, and a growing international footprint, The Medocann Group is ready to meet that future — and help shape it.
Interested in partnering with Medocann? Visit www.medocann.com or contact us (info@medocann.com) to explore how we can bring ultra-premium craft cannabis to your market — together.
Global Medical Cannabis Market Review 2026
A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.
What's covered
Premium Data Packs
Save 15%Pre-register for the Free Report
Be the first to receive the Global Medical Cannabis Market Review 2026 when it publishes in January.
Overwhelming Majority (80%) of Canadian Cannabis Now Sourced from Legal Distributors in Major Turnaround
Next PostWhat Cannabis Leaders Can Learn from Olympic Champions
Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, they have researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Related Posts
Related Posts
UK Police Finally Get Official Medical Cannabis Guidance More Than 7 Years After Legalisation
Over seven years after medical cannabis was legalised in the UK, the National Police Chiefs' Council has approved the first...
Germany’s Medical Cannabis Bill Faces Critical Test as Experts Warn of ‘Unenforceable’ Framework
As Trump's rescheduling executive order dominated the cannabis industry’s attention over the holiday period, Germany's controversial medical cannabis bill quietly...
Industry Leaders React to Historic Cannabis Rescheduling
CBD Company Founder Wins £137k Unfair Dismissal Award Amid Cannim Group Collapse
Veterans and Medical Cannabis: Can Private Clinics Fill NHS Treatment Gaps?
‘Blockbuster’ Cannabis Drug To Be Released in 2026
Cannabis Europa Paris
Europe’s leading cannabis policy, business and investment conference — bringing senior decision-makers together in Paris.
CONNECT
Related Posts
Related Posts
The Battle for Germany’s Medical Cannabis Market: Who’s Fighting for What
Today, (Wednesday, January 14), a public hearing will bring together 22 hand-picked experts for a debate on the future country's...
SOMAÍ and Universidade Lusófona Publish Peer-Reviewed Study Validating Full-Spectrum Oil Consistency
SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) specialising in cannabinoid-based medicines, together with Universidade Lusófona, has published their...
UK Police Finally Get Official Medical Cannabis Guidance More Than 7 Years After Legalisation
Over seven years after medical cannabis was legalised in the UK, the National Police Chiefs' Council has approved the first...
Germany’s Medical Cannabis Bill Faces Critical Test as Experts Warn of ‘Unenforceable’ Framework
As Trump's rescheduling executive order dominated the cannabis industry’s attention over the holiday period, Germany's controversial medical cannabis bill quietly...
Industry Leaders React to Historic Cannabis Rescheduling
President Donald Trump's executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled...
Recent Posts
Related Posts
What’s in Store for the Global Cannabis Industry in 2026?
After a broadly optimistic and reform-driven 2024, this year saw momentum beging to shift once again for the global cannabis...
There’s No UK Cannabis Industry Without UK Cultivation
The UK economic growth faces a paradox of two seemingly opposing pressures, yet both may be resolved by moving in...
Is Portugal About to Lose its Position as the ‘Gateway’ to Europe’s Largest Cannabis Markets?
Over the last five years, Portugal has built a reputation as the medical cannabis ‘doorway to Europe’, the go-to hub...
Business of Cannabis: New York 2025 – Key Takeaways
Business of Cannabis: New York 2025 arrived at a crucial moment not just for the local cannabis industry, but for...
Why is No One Talking About Germany’s Oversupply Problem?
Germany’s telemedicine-fuelled expansion has driven the value of its medical cannabis market up by hundreds of millions of euros in...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags